Novo Nordisk to explore how GLP-1 drugs can help patients with addiction
Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...
Medical Marketing & Media1d
Novo Nordisk welcomes patients to the Ozempic Era
With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.
Ozempic maker says its Australian market could be half the population
Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...
Are weight-loss drugs like Ozempic a forever medicine? Vikrant Shrotriya of Novo Nordisk India reacts
As the global demand for obesity treatments skyrockets, Vikrant Shrotriya discusses the complex nature of obesity, the ...
Shocking stories of people who went blind after taking Ozempic and Mounjaro
Weight loss drugs like Ozempic, while transformative in combating obesity, have been linked to irreversible vision impairment ...
Down 39%. Is Novo Nordisk Stock a Buy on the Dip?
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
Novo Nordisk shares are rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
Novo Nordisk Launches National "My Ozempic® Era" Campaign Celebrating Stories of Inspirational Ozempic® Patients
Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...
India Today on MSN2d
Why don't celebrities admit to taking Ozempic? Expert answers at India Today Conclave
Vikrant Shrotriya, Corporate Vice President & Managing Director of Novo Nordisk India, during a session on India Today Conclave 2025, said that many celebrities may not want to admit to taking Ozempic ...